Xencor Inc., of Monrovia, Calif., received a milestone payment from Merck & Co. Inc., of Whitehouse Station, N.J., through a subsidiary, triggered by the initiation of a phase I study of an undisclosed biologic drug candidate that uses Xencor's Xmab antibody engineering intellectual property (IP).